Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System
Launched by COCHLEAR · May 14, 2008
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Eighteen years of age or older at the time of implantation.
- • 2. Severe to profound (a threshold average of 2000, 3000, \& 4000 Hz \> 75dB HL) sensorineural hearing loss for frequencies \> 1500 Hz. Low-frequency thresholds up to and including 500 Hz should be no poorer than 60 dB HL.
- • 3. Consonant Nucleus Consonant (CNC) monosyllabic word recognition score (mean of two lists) between 10% and 60%, inclusive (i.e., 10% \<= score \<= 60%), in the ear to be implanted.
- • 4. CNC word recognition score in the contralateral ear equal to, or better than, the ear to be implanted but not more than 80%.
- • 5. English spoken as a primary language.
- Exclusion Criteria:
- • 1. Duration of severe-to-profound hearing loss greater than 30 years.
- • 2. Congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age).
- • 3. Medical or psychological conditions that contraindicate undergoing surgery.
- • 4. Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array.
- • 5. Conductive overlay of 15 dB or greater at two or more frequencies, in the range 250 to 1000 Hz.
- • 6. Hearing loss of neural or central origin.
- • 7. Diagnosis of Auditory Neuropathy.
- • 8. Active middle-ear infection.
- • 9. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices.
- • 10. Unwillingness or inability of the candidate to comply with all investigational requirements.
- • 11. Additional handicaps that would prevent or restrict participation in the audiological evaluations.
About Cochlear
Cochlear Limited is a global leader in implantable hearing solutions, dedicated to transforming the lives of individuals with hearing loss through innovative technology and comprehensive clinical research. With a strong commitment to advancing auditory rehabilitation, Cochlear conducts rigorous clinical trials aimed at evaluating the safety and efficacy of its products, including cochlear implants and bone conduction devices. The company collaborates with healthcare professionals and research institutions worldwide to ensure that its solutions meet the highest standards of quality and performance, ultimately enhancing patient outcomes and promoting accessibility to hearing health care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
John T Roland, MD
Principal Investigator
NYU MEDICAL CENTER
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials